Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy

Circulation Research

Volumn 95, Issue 10, 2004, Pages 1005-1011

  Stull, Linda B ^a   Leppo, Michelle K ^a   Szweda, Luke ^b   Gao, Wei Dong ^a   Marbán, Eduardo ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Division of Cardiology   (United States)

Author keywords

Contraction; Heart failure; Mice; Myocardial; Oxygen

Indexed keywords

ALLOPURINOL; CALCIUM; ISOPRENALINE; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC STIMULATION; CARDIOMYOPATHY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; LIPID PEROXIDATION; LONG TERM CARE; MALE; MOUSE; MYOFILAMENT; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; ALLOPURINOL; ANIMALS; ANTIOXIDANTS; CALCIUM SIGNALING; DRUG EVALUATION, PRECLINICAL; HEART FAILURE, CONGESTIVE; ISOPROTERENOL; LIPID PEROXIDATION; MALE; MICE; MICROFILAMENTS; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; OXIDATIVE STRESS; PROSPECTIVE STUDIES; RANDOM ALLOCATION; XANTHINE OXIDASE;

EID: 8844261207     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000148635.73331.c5     Document Type: Article

References (37)

1. de Jong JW, Schoemaker RG, de Jonge R, Bernocchi P, Keijzer E, Harrison R, Sharma HS, Ceconi C. Enhanced expression and activity of xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol. 2000;32:2083-2089.
2. Kogler H, Fraser H, McCune S, Altschuld R, Marban E. Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc Res. 2003;59:582-592.
3. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marban E, Hare JM. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:2407-2411.
4. Ekelund UEG, Harrison RW, Shokek O, Thakkar RN, Tunin RS, Senzaki H, Kass DA, Marban E, Hare JM. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res. 1999;85:437-445.
5. Saavedra WF, Paolocci N, Zeichner J, Mudrick D, Marban E, Kass DA., Hare JM. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underling mechanoenergetic uncoupling in the failing heart. Circ Res. 2002;90:297-304.
6. Gao WD, Liu Y, Marban E. Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle. Implications for the mechanism of stunned myocardium. Circulation. 1996;94:2597-2604.
7. Weisman HF, Bartow T, Leppo MK, Marsh HC, Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT, Janssen PM, Stull LB, Altschuld RA, Marban E. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis Selective contractile dysfunction of left, not right, ventricular myocardium in the SHHF rat Physiological determinants of contractile force generation and calcium handling in mouse myocardium. Science. 1990;249:146-151.
8. Gao WD, Backx PH, Azan-Backx M, Marban E. Myofilament Ca2+ sensitivity in intact versus skinned rat ventricular muscle. Circ Res. 1994;74:408-415.
9. Gao WD, Liu Y, Mellgren R, Marban E. Intrinsic myofilament alterations underlying the decreased contractility of stunned myocardium. A consequence of Ca2+-dependent proteolysis? Circ Res. 1996;78:455-465.
10. Janssen PM, Stull LB, Marban E. Myofilament properties comprise the rate-limiting step for cardiac relaxation at body temperature in the rat. Am J Physiol Heart Circ Physiol. 2002;282:H499-H507.
11. Janssen PML, Stull LB, Marban E. Myofilament properties comprise the rate-limiting step for cardiac relaxation at physiological temperature in rat myocardium. Am J Physiol Heart Circ Physiol. 2002;288:H499-H507.
12. Backx PH, Gao WD, Azan-Backx MD, Marban E. The relationship between contractile force and intracellular [Ca2+] in intact rat cardiac trabeculae. J Gen Physiol. 1995;105:1-19.
13. Stull LB, Leppo MK, Marban E, Janssen PM. Physiological determinants of contractile force generation and calcium handling in mouse myocardium. J Mol Cell Cardiol 2002;34:1367-1376.
14. Gao WD, Perez NG, Seidman CE, Seidman JG, Marban E. Altered cardiac excitation-contraction coupling in mutant mice with familial hypertrophic cardiomyopathy. J Clin Invest. 1999;103:661-666.
15. Perez NG, Gao WD, Marban E. Novel myofilament Ca2+-sensitizing property of xanthine oxidase inhibitors. Circ Res. 1998;83:423-430.
16. Beckman JS, Parks DA, Pearson JD, Marshall PA, Freeman BA. A sensitive fluorometric assay for measuring xanthine dehydrogenase and oxidase in tissues. Free Radic Biol Med. 1989;6:607-615.
17. Tsai L, Szweda PA, Vinogradova O, Szweda LI, Uchida K, Chae HZ, Stadtman ER. Structural characterization and immunochemical detection of a fluorophore derived from 4-hydroxy-2-nonenal and lysine Immunochemical detection of 4-hydroxynonenal protein adducts in oxidized hepatocytes. Proc Natl Acad Sci U S A. 1998;95:7975-7980.
18. Uchida K, Szweda LI, Chae HZ, Stadtman ER. Immunochemical detection of 4-hydroxynonenal protein adducts in oxidized hepatocytes. Proc Natl Acad Sci U S A. 1993;90:8742-8746.
19. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation, 1999;99:2658-2664.
20. Gao WD, Perez NG, Marban E. Calcium cycling and contractile activation in intact mouse cardiac muscle. J Physiol (Lond). 1998;507:175-184.
21. Brixius K, Mehlhorn U, Bloch W, Schwinger RH. Different effect of the Ca(2+) sensitizers EMD 57033 and CGP 48506 on cross-bridge cycling in human myocardium. J Pharmacol Exp Ther. 2000;295:1284-1290.
22. Zimmermann N, Boknik P, Gams E, Herzig JW, Neumann J, Scholz H. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure? Eur J Cardiothorac Surg. 1998;14:70-75.
23. Ukai T, Cheng CP, Tachibana H, Igawa A, Zhang ZS, Cheng HJ, Little WC. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation. 2001;103:750-755.
24. Eaton P, Li JM, Hearse DJ, Shattock MJ. Formation of 4-hydroxy-2-nonenal- modified proteins in ischemic rat heart. Am J Physiol. 1999;276: H935-H943.
25. Kogler H, Soergel DG, Murphy AM, Marban E. Maintained contractile reserve in a transgenic mouse model of myocardial stunning. Am J Physiol Heart Circ Physiol. 2001;280:H2623-H2630.
26. Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, Harrison RW, Zeichner J, Mudrick D, Marban E, Kass DA, Hare JM. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res. 2002;90:297-304.
27. Katz AM. A new inotropic drug: its promise and a caution. N Engl J Med. 1978;299:1409-1410.
28. Javadpour MM, Tardiff JC, Pinz I, Ingwall JS. Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J Clin Invest. 2003;112:768-775.
29. Blasig IE, Grune T, Schonheit K, Rohde E, Jakstadt M, Haseloff RF, Siems WG. 4-Hydroxynonenal, a novel indicator of lipid peroxidation for reperfusion injury of the myocardium. Am J Physiol 1995;269:H14-H22.
30. Srivastava S, Chandra A, Wang LF, Seifert WE, Jr., DaGue BB, Ansari NH, Srivastava SK, Bhatnagar A, Blasig IE, Grune T, Schonheit K, Rohde E, Jakstadt M, Haseloff RF, Siems WG, Eaton P, Li JM, Hearse DJ, Shattock MJ. Metabolism of the lipid peroxidation product, 4-hydroxy-trans-2-nonenal, in isolated perfused rat heart 4-Hydroxynonenal, a novel indicator of lipid peroxidation for reperfusion injury of the myocardium Release of 4-hydroxynonenal, an aldehydic mediator of inflammation, during postischaemic reperfusion of the myocardium Formation of 4-hydroxy-2-nonenal-modified proteins in ischemic rat heart. J Biol Chem. 1998;273:10893-10900.
31. Grune T, Siems WG, Schonheit K, Blasig IE. Release of 4-hydroxynonenal, an aldehydic mediator of inflammation, during postischaemic reperfusion of the myocardium. Int J Tissue React. 1993;15:145-150.
32. Earll JM, Saavedra M. Oxipurinol therapy in allopurinol-allergic patients. Am Fam Physician. 1983;28:147-148.
33. Alderman M, Aiyer KJ, Berry CE, Hare JM, Johnson RJ. Uric acid: role in cardiovascular disease and effects of losartan Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Curr Med Res Opin. 2004;20:369-379.
34. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol. 2002;2:126-130.
35. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Zeni P, Zardini P. Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. Am Heart J. 2002; 143:1107-1111.
36. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R. Effects of xanthine oxidase inhibition with allopurmol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105:2619-2624.
37. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart. 2002;87:229-234.